These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19559731)

  • 1. Monitoring of HIV-1 envelope-mediated membrane fusion using modified split green fluorescent proteins.
    Wang J; Kondo N; Long Y; Iwamoto A; Matsuda Z
    J Virol Methods; 2009 Nov; 161(2):216-22. PubMed ID: 19559731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Polar Region of the HIV-1 Envelope Protein Determines Viral Fusion and Infectivity by Stabilizing the gp120-gp41 Association.
    Lu W; Chen S; Yu J; Behrens R; Wiggins J; Sherer N; Liu SL; Xiong Y; Xiang SH; Wu L
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of HIV-1 by fusion inhibitors.
    Eggink D; Berkhout B; Sanders RW
    Curr Pharm Des; 2010; 16(33):3716-28. PubMed ID: 21128887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process.
    Bär S; Alizon M
    J Virol; 2004 Jan; 78(2):811-20. PubMed ID: 14694113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
    Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
    J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
    Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
    J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step.
    Barbouche R; Decroly E; Kieny MP; Fenouillet E
    Virology; 2000 Jul; 273(1):169-77. PubMed ID: 10891419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combined treatment with fusion inhibitor. HIV-1 viruses under control longer].
    MMW Fortschr Med; 2004 Apr; 146(15):68. PubMed ID: 15373030
    [No Abstract]   [Full Text] [Related]  

  • 9. Temperature-dependent intermediates in HIV-1 envelope glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal helical regions of HIV-1 gp41.
    Gallo SA; Clore GM; Louis JM; Bewley CA; Blumenthal R
    Biochemistry; 2004 Jun; 43(25):8230-3. PubMed ID: 15209519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A synthetic all D-amino acid peptide corresponding to the N-terminal sequence of HIV-1 gp41 recognizes the wild-type fusion peptide in the membrane and inhibits HIV-1 envelope glycoprotein-mediated cell fusion.
    Pritsker M; Jones P; Blumenthal R; Shai Y
    Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7287-92. PubMed ID: 9636141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors.
    Yu D; Su Y; Ding X; Zhu Y; Qin B; Chong H; Cui S; He Y
    Viruses; 2020 Mar; 12(3):. PubMed ID: 32197300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41.
    Gustchina E; Louis JM; Bewley CA; Clore GM
    J Mol Biol; 2006 Dec; 364(3):283-9. PubMed ID: 17010381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current status and challenges in the development of fusion inhibitors as therapeutics for HIV-1 infection.
    Tan JJ; Ma XT; Liu C; Zhang XY; Wang CX
    Curr Pharm Des; 2013; 19(10):1810-7. PubMed ID: 23092283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of HIV-1 fusion inhibitors targeting gp41.
    Lu K; Asyifah MR; Shao F; Zhang D
    Curr Med Chem; 2014 Jun; 21(17):1976-96. PubMed ID: 24350848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
    Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
    J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapies based on mechanisms of HIV-1 cell entry.
    Kilby JM; Eron JJ
    N Engl J Med; 2003 May; 348(22):2228-38. PubMed ID: 12773651
    [No Abstract]   [Full Text] [Related]  

  • 17. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.
    Pan C; Cai L; Lu H; Qi Z; Jiang S
    J Virol; 2009 Aug; 83(16):7862-72. PubMed ID: 19493996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-cell and virus-cell fusion assay-based analyses of alanine insertion mutants in the distal α9 portion of the JRFL gp41 subunit from HIV-1.
    Yamamoto M; Du Q; Song J; Wang H; Watanabe A; Tanaka Y; Kawaguchi Y; Inoue JI; Matsuda Z
    J Biol Chem; 2019 Apr; 294(14):5677-5687. PubMed ID: 30737278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 gp41: mediator of fusion and target for inhibition.
    Weiss CD
    AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
    Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S
    Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.